Core B: Biospecimen and Pathology Resources Core

核心 B：生物样本和病理学资源核心

• 批准号: 9071065
• 负责人: Payal Kapur
• 金额: $ 35.68万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9071065
• 关键词: Academia; Address; Adult; Animal Model; Archives; Basic Science; Benchmarking; Biogenesis; Biological Assay; Blood; Blood specimen; CLIA certified; Cancer Biology; Cancer Center; Candidate Disease Gene; Carcinoma; Caring; Cell Culture Techniques; Cell Line; Child; Childhood; Clear Cell; Clinic; Clinical; Collaborations; Communication; Communities; Cryopreserved Tissue; DICER1 gene; DNA; Dana-Farber Cancer Institute; Data; Data Reporting; Dimethyl Sulfoxide; Ensure; Evaluation; Formalin; Foundations; Freezing; Genes; Genetic; Genomics; Goals; Hereditary Leiomyomatosis and Renal Cell Cancer; Histology; Histopathology; Human; Image; Image Analysis; Immunohistochemistry; Implant; In Situ Hybridization; Industry; Institution; Journals; Kidney; Kidney Neoplasms; Laboratories; Laboratory Research; Life; Malignant Neoplasms; Malignant childhood renal neoplasm; Medical center; Metabolic; MicroRNAs; Mission; Molecular; Mus; Mutation; National Cancer Institute; Nature; Nephrectomy; Nephroblastoma; Papillary; Paraffin Embedding; Paraneoplastic Syndromes; Pathologic; Pathologist; Pathology; Patients; Peripheral Blood Mononuclear Cell; Plasma; Primary Neoplasm; Principal Investigator; Protocols documentation; Publishing; Quality Control; RNA; RNASE3L gene; Radiation; Renal Cell Carcinoma; Renal carcinoma; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resource Sharing; Resources; SNP array; Sampling; Services; Shipping; Ships; Slide; Somatic Mutation; Specimen; Staging; Testing; Texas; Therapeutic Intervention; Time; Tissue Microarray; Tissues; Transgenic Animals; Translational Research; Tumor Bank; Tumor Cell Line; Tumor Markers; Tumor Tissue; Universities; Xenograft procedure; ablative procedure; base; biobank; cancer cachexia; cancer cell; cohort; drug sensitivity; drug testing; exome; exome sequencing; experience; inhibitor/antagonist; knockout animal; laser capture microdissection; metabolomics; novel; oncology; personalized medicine; pre-clinical; programs; repository; tertiary care; tissue processing; tissue resource; transcription factor; transcriptome sequencing; tumor; whole genome

Project Summary The aims of the Biospecimen and Pathology Resources (BPR) Core (Core B) are to facilitate the storage and distribution of comprehensively annotated, high-quality biospecimens and their derivatives, and to provide professional and technical pathology services to the principal investigators and collaborators of our SPORE and Kidney Cancer Program. All four SPORE projects utilize Core B, which is critical to achieving their aims. It is an indispensable component of our SPORE and leverages and expands (without duplicating) existing pathology resources in our National Cancer Institute (NCI)-designated Simmons Cancer Center and Children’s Medical Center. We deliver basic histology, immunohistochemistry (IHC), in situ hybridization (ISH), tissue microarrays, whole slide imaging, image analysis, and laser-capture microdissection services and make available unique cancer tissue-derivatives such as primary cancer cell cultures and cell lines, cryopreserved tissues, DNA, RNA and patient-derived xenografts (PDX or tumorgrafts). This Core provides expertise in histomorphologic evaluation of human kidney tumors, human tumorgrafts in mice, kidney tumors in transgenic and knockout animal models, and in the interpretation of IHC and ISH assays. The BPR Core develops IHC and molecular assays and has experience in the deployment of CLIA-certified laboratory tests, such as our BAP1 IHC test – a popular assay developed by Dr. Kapur (Director, Core B) at UTSW and applied to >3000 samples from >10 institutions. The BPR Core currently has: >640 fresh frozen and >3000 paraffin-embedded tissues from renal tumors, respectively; a unique live-tissue repository of >600 kidney tumor tissues viably preserved in DMSO that are amenable to mechanistic studies to address questions arising from genomic and other studies of inert tissues; 90 independent orthotopically-passaged tumorgraft lines, including lines from rare tumors (such as Hereditary Leiomyomatosis and RCC); >75 primary tumor cell lines representing a wide variety of banked tumors; and integrated genomic analyses (exome sequencing, RNA-Seq, and SNP data) from >300 tumors. The BPR Core provides routine quality controls for SPORE investigators to ensure that the tissues are optimal, and several of our protocols have been published in Nature Protocols and serve as benchmarks in the fields of tissue processing for integrated genomic analyses and tumorgraft utilization for preclinical drug testing. Our repository has had significant utilization, with >1000 samples having been shipped to collaborators both internally, as well as externally. Tumorgrafts have been extensively utilized to evaluate RCC drug sensitivity, study radiation responsiveness, explore tumor biomarkers, understand cancer biology (including tumor-induced cachexia and paraneoplastic syndromes), and dissect metabolic derangements in RCC. Studies with these tissues have been published in high-impact journals such as Nature Genetics, Nature Communications, and Lancet Oncology. Our Core promotes flourishing collaborations among our SPORE investigators, investigators from other SPOREs, and other investigators in academia and industry.

项目摘要 生物标本和病理学资源（BPR）核心（核心B）的目的是促进储存和 分发全面注释的高质量生物标本及其衍生物，并提供 专业和技术病理学服务的主要研究者和合作者，我们的孢子 和肾癌项目。所有四个SPORE项目都使用Core B，这对实现其目标至关重要。它 是我们的SPORE不可或缺的组成部分，并利用和扩展（不重复）现有的 病理资源在我们的国家癌症研究所（NCI）-指定西蒙斯癌症中心和儿童 医学中心我们提供基础组织学、免疫组织化学（IHC）、原位杂交（ISH）、组织学和免疫组织化学。 微阵列、全载玻片成像、图像分析和激光捕获显微切割服务， 可用的独特的癌组织衍生物，如原代癌细胞培养物和细胞系，冷冻保存 组织、DNA、RNA和患者来源的异种移植物（PDX或肿瘤移植物）。该核心提供以下方面的专业知识 人肾肿瘤、小鼠中人肿瘤移植物、转基因小鼠中肾肿瘤的组织形态学评价 和基因敲除动物模型，以及在IHC和ISH测定的解释中。BPR核心开发IHC 和分子检测，并在部署CLIA认证的实验室测试方面拥有经验，例如我们的 BAP 1 IHC检测-由UTSW的Kapur博士（核心B主任）开发的流行检测方法，适用于>3000 样本来自10个以上机构。BPR核心目前有：>640新鲜冷冻和>3000石蜡包埋 分别来自肾肿瘤的组织;一个独特的活组织库，可储存超过600种肾肿瘤组织， 保存在DMSO中，适合于机制研究，以解决基因组和 惰性组织的其他研究; 90个独立的原位传代肿瘤移植物系，包括来自罕见的 肿瘤（例如遗传性平滑肌瘤病和肾细胞癌）; >75种原发性肿瘤细胞系代表广泛的 各种库存肿瘤;和综合基因组分析（外显子组测序、RNA-Seq和SNP数据） 超过300个肿瘤。BPR核心为SPORE调查人员提供常规质量控制，以确保 组织是最佳的，我们的几个协议已发表在自然协议，并作为 用于整合基因组分析的组织处理和用于 临床前药物测试我们的存储库已经有了很大的利用率，已经运送了超过1000个样本 内部和外部的合作者。肿瘤移植物已被广泛用于评估 RCC药物敏感性，研究放射反应性，探索肿瘤生物标志物，了解癌症生物学 （包括肿瘤引起的恶病质和副肿瘤综合征），并剖析代谢紊乱， RCC。这些组织的研究已发表在高影响力的期刊上，如Nature Genetics，Nature 通讯和柳叶刀肿瘤学。我们的核心促进我们的SPORE之间蓬勃发展的合作 调查人员、其他SPORE的调查人员以及学术界和工业界的其他调查人员。